Three years ago, a 36-year-old woman surnamed Xiaohe fell while hiking. The impact caused a complete cervical spinal cord injury: she lost nearly all movement in her arms and legs, and after two years of conventional rehabilitation she could still barely lift her arms. Eating, brushing her hair, getting through a day — all of it depended on her family.
In the first half of 2026 she enrolled in a multi-centre registration clinical trial at Henan Provincial People's Hospital. In July she became the first person in Central China to receive a domestically developed "BeiNao-1" semi-invasive wireless brain–computer interface. After the device was switched on and calibrated, she completed a series of fine movements — grasping, transferring objects — using nothing but motor imagery.
Her case is one of more than forty now on record.
Key takeaways
- Scale: NEUCYBER (Beijing Xinzhida Neural Technology) disclosed in August 2026 that BeiNao-1 has been implanted in more than 40 patients, up from 10 in April 2026.
- Approach: BeiNao-1 is semi-invasive — a 128-channel flexible high-density film electrode is placed on the outer surface of the dura (epidural), so the device never penetrates brain tissue.
- First of its kind: It is reported as the world's first semi-invasive BCI to exceed 100 channels in a fully wireless, fully implanted package.
- Durability: The longest-implanted patient has lived with the device for over 18 months; the company reports the system has accumulated more than 100,000 hours of safe operation.
- Targets: Spinal cord injury, stroke and amyotrophic lateral sclerosis (ALS), for both functional restoration and compensatory therapy.
- Path to market: A formal GCP multi-centre registration trial began on 31 March 2026 at Beijing Tiantan Hospital and Xuanwu Hospital. The company has said it aims to file for medical device registration in early 2027.
Why "semi-invasive" is the strategic choice
Brain–computer interfaces are usually sorted into two camps. Invasive systems place electrodes inside brain tissue and capture exquisite signal, but they require opening the dura and carry long-term risks of inflammation, scarring and bleeding. Non-invasive systems (EEG caps) are safe and cheap but read a blurred signal through the skull.
China has been unusual in treating the middle path as a first-class strategy. Leading clinical centres have argued that the epidural route — a small bone window, electrodes laid on the dura, no contact with brain tissue — reaches an internationally recognised balance between safety and signal fidelity. It is why the approach has become the priority technology route for clinical promotion in the country.
The engineering supports the claim. BeiNao-1 pairs 128-channel synchronous acquisition with 30 kHz sampling, and reports motor-intent decoding latency of under 100 milliseconds — fast enough for fine motor control and for decoding Chinese speech. The implanted unit supports wireless data transmission and wireless charging, with no wires crossing the skin, so patients are not tethered to a hospital for rehabilitation.
The clinical picture
The trial population is deliberately broad. Early implants included four spinal cord injury patients, two stroke patients with hemiplegia, and one person with speech impairment from ALS.
Reported trajectories include a patient with thoracic/lumbar spinal cord injury and five years of lower-limb paralysis who, through brain-controlled spinal cord stimulation plus a rehabilitation exoskeleton, progressed from ASIA A to ASIA B within three months, regained voluntary bladder and bowel control, was walking with braces and crutches by month five, and reached ASIA C by month six. Surgeons involved have also noted that no serious complications have appeared across the cohort, with signals remaining stable.
That last point matters more than any single benchmark. A BCI is not a normal implantable device: the surgery is the beginning, not the end. Patients and devices have to learn each other, which is why the field in China is exploring a new clinical role — a "brain–computer interface adaptation physician" — to build the workforce needed for scale.
A second contender, and a growing field
NEUCYBER is not alone. Neuracle Technology (Shanghai) received regulatory clearance for its product in March 2026 and performed its first implant after its listing in July 2026 — a notably fast move from approval to clinical use. Industry analysis has described Neuracle as the current No. 1 player in China's BCI sector, with NEUCYBER the strongest contender for No. 2.
Both companies were incubated out of the same national research base: NEUCYBER was founded in 2023 with investment from the Beijing municipal government and Zhongguancun Development Group, operating under the Beijing Institute for Brain Science and Brain-Inspired Research as the implementing body of Beijing's "brain–machine system enhancement plan."
What comes next
BeiNao-1's sibling, BeiNao-2, takes the invasive route at higher precision: a 512-channel wireless fully implanted prototype has been built and is in large-animal testing, with information transfer rates reported above 7 bits per second in animal experiments and human implants planned from the end of 2026.
Running in parallel, NEUCYBER has signed an agreement to build its first-phase R&D and production base at the Zhongguancun (Changping) Brain Science and Brain–Computer Interface Industrial Park — linking research, clinical work and manufacturing in one place. That is the tell: this is no longer a laboratory programme, it is an industrial one.
Figures in this article are drawn from company disclosures and hospital statements reported by Chinese and industry media in 2026. Clinical outcomes vary by patient; BCI therapy for spinal cord injury, stroke and ALS should be understood as an area of ongoing clinical research.